GlaxoSmithKline (GSK) has filed its shingles vaccine Shingrix for US regulatory approval, the drugmaker said yesterday, bringing the potential $1bn (€918m)-a-year seller a step closer to market.

The world’s first malaria vaccine got a green light from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.